As an example of how CMS would identify the payment amount benchmark period as proposed under 428.202(c)(3), if a Part D rebatable drug that was first approved or licensed by the FDA on July 7, 2021, and has a first marketed date of September 15, 2021, does not have AMP reported in the period beginning January 1, 2021 and ending September 30, 2021, but does have AMP reported for the second calendar quarter of 2022, CMS would identify the payment amount benchmark period for such drug as calendar year 2022 (that is, January 1, 2022, through December 31, 2022)
CMS would provide the ACO with ( written notification of the total amount due for the full recoupment of advance investment payments, and the ACO must pay such amount within 90 days after the receipt of such notification
Tasdighi emphasized that this doesnt mean cessation doesnt have immediate effects
References [edit] "Nicotine levels in American smokeless tobacco products"
Dermatological Care